Sandra von Meier
Sandra von Meier started her career as a scientist working on tumor vaccines at Medigene AG, a biotech company south of Munich. Beginning of 2001 she was promoted into business development and was responsible for partnering of Medigene projects as well as in-licensing of new projects. She was part of the team closing the marketing partnership with Astellas for Medigene's prostate cancer product Eligard.
In 2008 Sandra was promoted to Senior Manager Business Development having the main responsibility for Medigene's lead oncology project. From 2011 she took on the additional responsibility of project coordination for this Phase II oncology project leading the respective scientific team and also supervising an additional Phase II study (IIT) conducted in HER negative breast cancer.
In 2012 she closed the first partnering deal for Medigene's lead oncology project and was promoted in 2013 to Head of Business Development of Medigene. In this function she reported directly to the board and closed the worldwide partnership for Medigene's oncology project. In 2013 she also took on partnering responsibility for Medigene's autoimmune development candidate which was licensed to Falk Pharma in spring 2014. The same year still Sandra joined Merck’s Global Business Development Team with responsibility for Oncology and more recently Immuno Oncology transactions. In this function she was part of the Merck Pfizer deal team which closed as one of the largest transactions for a preclinical candidate in autumn last year. She is currently the Director Business Development Oncology in Merck Serono.
Sandra studied Biochemistry at the FU Berlin and then moved to London in 1995 for her Diploma at the Institute of Cancer Research. In 1996 she was awarded a joint PhD scholarship from the Ludwig Institute for Cancer Research in London in collaboration with GlaxoSmithKline in Stevenage. Sandra received her PhD from University College London in 1999.